Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Vurdering av en ikke-invasiv enhet i behandling av åpen abdomen (AbCLO) (AbCLO)

10. november 2026 oppdatert av: Tufts Medical Center

Vurdering av en ikke-invasiv enhet i behandling av åpen abdomen (AbCLO) - Pilotstudie

The goal of this single-center, prospective Cohort Interventional study is to perform a pilot study of the AbCLO (Abdominal Wall Closure) device in patients with Open Abdomen. The main question it aims to answer is:

• Does the Abdominal Wall Closure Device (AbCLO) increase the likelihood of primary facial closure in cases of open abdomen when compared to historical controls?

Participants will be cases of open abdomen who underwent emergency surgery for Trauma or Acute Care Surgery, will have the AbCLO device. These will be compared to historical controls managed at the same center.

Studieoversikt

Status

Fullført

Forhold

Detaljert beskrivelse

This is a Single center matched prospective cohort study. It will be performed at Tufts Medical Center (TMC).

The cohort (interventional) patients will receive the standard of care (Lahey bag, Ioban and closed suction drains) in addition to the study intervention (AbCLO Device).

The control group is retrospective patients that were previously managed at the same center, regardless of the technique or the device used to close the OA.

The total sample size is 60 patients, 15 in the treatment arm from TMC and 45 in the control arm (45 from TMC). The treatment arm will be matched to historical control based on the following pre-specified variables:

  1. Age
  2. Diagnosis: trauma case vs acute general surgery cases,
  3. Assessment of severity: Injury severity scores (ISS) for Trauma cases and APACHEII score for acute general surgery cases

Outcome Data:

  1. Primary Outcome: Proportion of patients achieved primary facial closure within 14 days. (This is defined as approximation of the fascia on either side of the midline to perform suture closure without using any mesh or additional procedures. From our experience, most open abdomen is usually closed within 7-10 days. We decided to put any closure more than 14 days is considered failure of the device).
  2. Proportion of patients that require component separation and/or mesh closure to obtain fascial closure, (if we need to use mesh or do additional procedure to close the abdomen, this is considered failure rate of the ABCLO device)
  3. Percentage of patients requiring additional device, such as Whitman's patch to maintain fascial closure. (this is also considered failure of the ABCLO device)
  4. The time from inclusion to complete abdominal wall fascial closure (as defined above) prior to discharge. (Duration of patients that require the abdomen to be open)
  5. Percentage of patients developing pressure ulcers (as a possible complication of the device)
  6. Duration of mechanical ventilation, ICU length of stay and hospital length of stay (to examine the indirect effects of primary fascial closure on these outcomes)
  7. Total cost per patient before and after application of the ABCLO from ICU admission to closure of the abdomen.

Studietype

Intervensjonell

Registrering (Faktiske)

15

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Los Angeles, California, Forente stater, 90033
        • Los Angeles County + University of Sothern California Medical Center
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02111
        • Tufts Medical center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Adults more than 18 years of age, and less than 100 years of age
  2. Admitted to the trauma and acute care surgery service, underwent damage control laparotomy and left with an open abdomen (OA). Trauma or Emergency General Surgery, such as perforated viscus, Bowel obstruction or abdominal compartment syndrome.

Exclusion Criteria:

  1. Pregnant patients
  2. Patients who lost any portion of the abdominal wall that preclude primary abdominal wall closure
  3. Patient who previously had a ventral hernia before having an open abdomen
  4. Patient who already had a previous mesh repair
  5. Burn patients

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: ABCLO Group

The cohort (interventional) patients will receive the standard of care (Lahey bag, Ioban and closed suction drains) in addition to the study intervention (AbCLO Device).

They will receive the standard of care (Lahey bag covering the bowel, 2 drains in the subcutaneous tissue and Ioban covering everything). The AbClO device has two Rectus Muscle Splints (RMS) to stabilize the rectus abdominis (preventing buckling of these muscles and stabilize the circumferential dynamic retainer (CDR)). The CDR is passed behind the patient's back. The RMSs are positioned on the abdominal wall approximately 2 cm lateral to the wound edges on each side. Additional padding can be applied underneath the RMS. The CDR is passed between the cross bar and the locking strip of each RMS and stretched until taut. The locking strips are locked in position. Four tensioners bridge across the OA from one RMS to the other. Gauze packs should be interposed between the undersurface of the tensioners and the surface of the temporary abdominal coverage to prevent friction. The Tensioners are tightened progressively until complete facial closure.

Ingen inngripen: Historical Controls

The control group is retrospective patients that were previously managed at the same center, regardless of the technique or the device used to close the OA.

At TMC, we have a previously collected data bank of all open abdomen managed at our center. This data bank is approved by IRB. This data bank has 170 patients in total. we will use 45 patients from the data bank to be matched to the interventional group (15 patients) to have a total of 45 patients from TMC. We will obtain EMR data from operating room records if we need additional more patients.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Primary Fascial Closure
Tidsramme: 14 days

Proportion of patients achieved primary facial closure within 14 days. (This is defined as approximation of the fascia on either side of the midline to perform suture closure without using any mesh or additional procedures.

14 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The need for additional procedure to perform fascial closure
Tidsramme: 14 days

Proportion of patients that require component separation and/or mesh closure to obtain fascial closure

14 days
The need for additional device
Tidsramme: 14 days

Percentage of patients requiring additional device, such as Whitman's patch to maintain fascial closure

14 days
Duration of open abdomen
Tidsramme: 14 days

The time from inclusion to complete abdominal wall fascial closure (as defined above) prior to discharge.

14 days
Device complications
Tidsramme: 14 days

Percentage of patients developing pressure ulcers

14 days
Duration of mechanical ventilation
Tidsramme: 14 days

The duration from intubation to liberation off mechanical ventilator.

14 days
ICU length of stay and Hospital length of stay
Tidsramme: 14 days

ICU length of stay from admission to leaving the ICU. Hospital length of stay from admission to discharge

14 days
cost
Tidsramme: 14 days

Total cost per patient before and after application of the ABCLO from ICU admission to closure of the abdomen

14 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Mohammed A. Bawazeer, MD, Tufts Medical Center

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. februar 2024

Primær fullføring (Faktiske)

30. oktober 2026

Studiet fullført (Faktiske)

30. oktober 2026

Datoer for studieregistrering

Først innsendt

29. januar 2024

Først innsendt som oppfylte QC-kriteriene

29. januar 2024

Først lagt ut (Faktiske)

5. februar 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • STUDY00003444

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere